Please assess the completion status of the following clinical trial:

Trial Title: Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Core Study:~Inclusion criteria:~* Meeting the American College of Rheumatology (ACR) 1977 preliminary criteria for the classification of acute arthritis of primary gout~* Onset of current acute gout flare within 5 days prior to study entry~* Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS)~* History of ≥ 3 gout flares within the 12 months prior to study entry~* Contraindication, or intolerance, or lack of efficacy for non-steroidal anti-inflammatory drugs (NSAID) and/or colchicine~Exclusion criteria:~* Rheumatoid arthritis, evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis~* Presence of severe renal function impairment~* Use of specified pain relief medications or biologics (corticosteroids, narcotics, paracetamol/acetominophen, ibuprofen, colchicine, IL-blocker, and tumor necrosis factor inhibitor within specified periods prior to study entry~* Live vaccinations within 3 months prior to randomization~* Requirement for administration of antibiotics against latent tuberculosis (TB)~* Refractory heart failure (Stage D)~* Unstable cardiac arrhythmias or unstable symptomatic coronary ischemia~* Any active or recurrent bacterial, fungal, or viral infection~Extension Study 1:~Inclusion:~- Completion of the Core study. A patient was defined as completing the core study if they completed the study up to and including visit 7.~Exclusion:~- Continuation in this extension study was considered inappropriate by the treating physician.~Extension Study 2:~Inclusion Criteria:~* Completion of the first extension study CACZ885H2357E1. A patient was defined as completing the first extension study if they completed the study up to and including Visit 10).~Exclusion Criteria:~-Continuation in this second extension study was considered inappropriate by the treating physician.~Other protocol-defined inclusion-exclusion criteria applied to the core and extension studies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Canakinumab 150 mg (Type: EXPERIMENTAL): Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to receive open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year, for a total duration of 18 months.
- Triamcinolone acetonide 40 mg (Type: ACTIVE_COMPARATOR): Participants received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to switch to open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year. Triamcinolone acetonide was not to be administered in the second extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).